MO02. A Rare Case of Left Atrial Primary Malignant Nerve Sheath Tumour: Case Report
Presented During: Breakfast Abstract Video Session
National Heart Centre Singapore
Singapore - Contact Me
Dr Alicia Xue Fen Chia graduated from the University of Southampton, UK. She began her training in Cardiothoracic Surgery in Singapore in 2012 and was appointed as Consultant Surgeon at the National Heart Centre Singapore in February 2019.
Dr Chia has experience in all adult cardiac surgery. In addition, she completed a one-year fellowship in Pulmonary Endarterectomy Surgery at the Royal Papworth Hospital, Cambridge, UK from 2021 to 2022.
Friday, May 5, 2023: 7:08 AM - 7:16 AM
8 Minutes
New York Hilton Midtown
Room: Grand Ballroom
Description
Objective:
Malignant peripheral nerve sheath tumor (MPNST) is a rare soft tissue sarcoma, accounting for approximately 2% of all sarcomas. It has a high rate of local recurrence and metastatic dissemination. Amongst all phenotypes of malignant primary cardiac tumors, MPNST is exceedingly rare with an incidence of 0.75% of all cardiac tumors. To date, only a handful of cases have been reported in the literature. Due to its scarcity, little is known about this disease entity and its optimal course of treatment. The current preferred course of treatment is by full surgical resection of the tumor, followed by adjuvant radiotherapy and chemotherapy.
Case video summary:
We report a unique case of a 50-year-old, previously healthy man, presenting with symptoms of congestive heart failure. Investigations revealed a large left atrial (LA) mass prolapsing across the mitral valve into the left ventricle during diastole, resulting in mitral inflow obstruction.
The patient underwent successful surgical resection of the left atrial tumor the next day. Intraoperative evaluation showed an atypical location of the mass arising from the posterolateral wall of the LA, extending into the left pulmonary veins and left atrial appendage. This heightened our suspicion of a malignant cardiac neoplasm. Histological examination confirmed the diagnosis of MPNST. The patient unfortunately had distant metastasis to the brain and vertebral body prior to commencement of chemotherapy.
Conclusions: Despite current aggressive multimodal therapy, the prognosis of patients with MPNST remains dismal with a mean survival ranging from 3 months to 1 year. Even after optimal radical resection, a significant proportion of patients (40-70%) develop local recurrence or distant metastases, usually within 1 year. Available therapies offer very limited benefits to patients with MPNST. Further research is required for new therapies.
Malignant peripheral nerve sheath tumor (MPNST) is a rare soft tissue sarcoma, accounting for approximately 2% of all sarcomas. It has a high rate of local recurrence and metastatic dissemination. Amongst all phenotypes of malignant primary cardiac tumors, MPNST is exceedingly rare with an incidence of 0.75% of all cardiac tumors. To date, only a handful of cases have been reported in the literature. Due to its scarcity, little is known about this disease entity and its optimal course of treatment. The current preferred course of treatment is by full surgical resection of the tumor, followed by adjuvant radiotherapy and chemotherapy.
Case video summary:
We report a unique case of a 50-year-old, previously healthy man, presenting with symptoms of congestive heart failure. Investigations revealed a large left atrial (LA) mass prolapsing across the mitral valve into the left ventricle during diastole, resulting in mitral inflow obstruction.
The patient underwent successful surgical resection of the left atrial tumor the next day. Intraoperative evaluation showed an atypical location of the mass arising from the posterolateral wall of the LA, extending into the left pulmonary veins and left atrial appendage. This heightened our suspicion of a malignant cardiac neoplasm. Histological examination confirmed the diagnosis of MPNST. The patient unfortunately had distant metastasis to the brain and vertebral body prior to commencement of chemotherapy.
Conclusions: Despite current aggressive multimodal therapy, the prognosis of patients with MPNST remains dismal with a mean survival ranging from 3 months to 1 year. Even after optimal radical resection, a significant proportion of patients (40-70%) develop local recurrence or distant metastases, usually within 1 year. Available therapies offer very limited benefits to patients with MPNST. Further research is required for new therapies.
Presentation Duration
5-minute presentation; 3-minute discussion